title: Primary central nervous system lymphoma in a patient treated with natalizumab.
authors.forename: Remy
authors.initials: R
authors.lastname: Phan-Ba
authors.forename: Bettina
authors.initials: B
authors.lastname: Bisig
authors.forename: Manuel
authors.initials: M
authors.lastname: Deprez
authors.forename: Bernard
authors.initials: B
authors.lastname: De Prijck
authors.forename: Gael
authors.initials: G
authors.lastname: Delrue
authors.forename: Christian
authors.initials: C
authors.lastname: Herens
authors.forename: Gustave
authors.initials: G
authors.lastname: Moonen
authors.forename: Shibeshih
authors.initials: S
authors.lastname: Belachew
authors.forename: Laurence
authors.initials: L
authors.lastname: de Leval
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001921:Brain / Q000473:pathology; D016543:Central Nervous System Neoplasms / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008223:Lymphoma / Q000188:drug therapy*; D008279:Magnetic Resonance Imaging; D008297:Male; D000069442:Natalizumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000069442:Natalizumab